# Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

> **NCT07651475** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Liping Dou** · enrollment: 32 (estimated)

## Conditions studied

- R/R AML

## Interventions

- **DRUG:** BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, Chidamide, and G-CSF

## Key facts

- **NCT ID:** NCT07651475
- **Lead sponsor:** Liping Dou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2026-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07651475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07651475, "Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07651475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*